NCT02612610View on ClinicalTrials.gov

A 12-Week Study in Participants With Refractory Chronic Cough (MK-7264-012)

PHASE2CompletedINTERVENTIONAL
Enrollment

253

Participants

Timeline

Start Date

December 15, 2015

Primary Completion Date

October 31, 2016

Study Completion Date

November 4, 2016

Conditions
Refractory Chronic Cough
Interventions
DRUG

Gefapixant

Gefapixant administered as one 7.5 mg, 20 mg, or 50 mg tablet twice daily, depending upon randomization.

DRUG

Placebo (for gefapixant)

All Listed Sponsors
lead

Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT02612610 - A 12-Week Study in Participants With Refractory Chronic Cough (MK-7264-012) | Biotech Hunter | Biotech Hunter